3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Chor-Sang ChimShaji K KumarVincent Kai Chung WongMichael Cheong NgaiYok Lam KwongPublished in: Hematology (Amsterdam, Netherlands) (2021)
This 3-weekly dara-IMiD-dex regimen preserves a high efficacy with rapid, deep responses including MRD-ve and PET-ve CR, hence a cost-effective regimen.